ResearchMoz

Immunovaccine, Inc. Product Pipeline Review 2012

Global Markets Direct
Published Date » 2012-10-31
No. Of Pages » 84
     
  Immunovaccine, Inc. Product Pipeline Review 2012  
   
 Global Market Directs pharmaceuticals report, ImmunoVaccine Technologies Inc. Product Pipeline Review 2012 provides data on the ImmunoVaccine Technologies Inc.s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.  
   
 This report is built using data and information sourced from Global Markets Directs proprietary databases, ImmunoVaccine Technologies Inc.s corporate website, SEC filings, investor presentations and featured press releases, both from ImmunoVaccine Technologies Inc. and industry-specific third party sources, put together by Global Markets Directs team.  
   
  Scope...
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Immunovaccine, Inc. Snapshot 7
Immunovaccine, Inc. Overview 7
Key Information 7
Key Facts 7
Immunovaccine, Inc. – Research and Development Overview 8
Key Therapeutic Areas 8
Immunovaccine, Inc. – Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products –  Monotherapy 12
Pipeline Products – Combination Treatment Modalities 13
Immunovaccine, Inc. – Pipeline Products Glance 14
Immunovaccine, Inc. Clinical Stage Pipeline Products 14
Phase I Products/Combination Treatment Modalities 14
Immunovaccine, Inc. – Early Stage Pipeline Products 15
Pre-Clinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Immunovaccine, Inc. – Drug Profiles 17
Anthrax Vaccine 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Cocaine Addiction Vaccine 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
DPX-0907 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
DPX-Survivac 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
DPX-Survivac + Low Dose Cyclophosphamide 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Hepatitis B Vaccine 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
HPV Vaccine 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
IRX-2 + DepoVax 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Malaria Vaccine 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Pandemic Influenza Vaccine 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Respiratory Syncytial Virus Vaccine 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Vaccine For Multifiloviruses 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Immunovaccine, Inc. – Pipeline Analysis 32
Immunovaccine, Inc. – Pipeline Products by Therapeutic Class 32
Immunovaccine, Inc. – Pipeline Products by Route of Administration 33
Immunovaccine, Inc. – Pipeline Products By Mechanism of Action 34
Immunovaccine, Inc. –  Recent Pipeline Updates 35
Immunovaccine, Inc. - Discontinued Pipeline Products 38
Discontinued Pipeline Product Profiles 38
DPX-Pseudomonas 38
Immunovaccine, Inc. – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Immunovaccine, Inc., Recent Developments 40
Immunovaccine, Inc.- Press Release 40
Oct 09, 2012: Immunovaccine Reports Positive Interim Results From Phase I Study Of Ovarian Cancer Vaccine Candidate DPX-Survivac 40
Aug 06, 2012: Immunovaccine Announces Publication Of Positive Clinical Trial Results For DPX-0907 In Journal Of Translational Medicine 41
Jun 20, 2012: Immunovaccine Announces Presentation Of DPX-Survivac Data At Federation of Clinical Immunology Societies Conference 43
Jun 04, 2012: Immunovaccine Presents Positive Phase I Results Of DPX-0907 In Multiple Cancers At ASCO Annual Meeting 2012 44
May 29, 2012: Immunovaccine To Present Clinical Data On DPX-0907 Cancer Vaccine At 2012 ASCO Annual Meeting 45
Apr 03, 2012: Immunovaccine Presents Findings Of Cancer Vaccine Studies At AACR Meeting 45
Jan 04, 2012: Immunovaccine Initiates Phase I Trial Of DPX-Survivac Cancer Vaccine 46
Dec 10, 2009: Immunovaccine Inc. Announces Approval Of Investigational Drug Application For Its Therapeutic Cancer Vaccine, DPX-0907 47
Dec 09, 2009: Immunovaccine Receives Clearance From FDA For Phase 1 Clinical Trial For Its Therapeutic Cancer Vaccine, DPX-0907 47
Jul 14, 2009: ImmunoVaccine Technologies Licenses Immunotope’s Breast, Ovarian and Prostate Cancer Antigens 48
Financial Deals Landscape 49
Immunovaccine, Inc., Deals Summary 49
Immunovaccine, Inc., Pharmaceuticals & Healthcare, Deal Details 51
Partnerships 51
Immunovaccine Enters Into Co-Development Agreement With Weill Cornell Medical College For Anti-Cocaine Vaccine 51
ImmunoVaccine Technologies Enters Into Research Agreement With CIMAB 52
Immunovaccine Technologies Enters Into Research Agreement With OncoTherapy Science 53
ImmunoVaccine Enters Into Agreement With IRX Therapeutics 54
Immunovaccine Enters Into Co-Development Agreement With Oncothyreon 55
Immunovaccine Enters Into Research Agreement With Vaxil BioTherapeutics 56
ImmunoVaccine Enters Into Research Agreement With Dana-Farber 57
ImmunoVaccine Enters Into Research Agreement With National Cancer Institute 62
Immunovaccine Expands Research Agreement With Defence Research And Development Canada 63
ImmunoVaccine Technologies Enters Into Agreement With Scancell 64
ImmunoVaccine Enters Into Research Agreement With Yokohama City University 65
ImmunoVaccine Technologies Enters Into Research Agreement With FIT Biotech 66
ImmunoVaccine Technologies Enters Into Agreement With NRC Institute for Biodiagnostics 67
ImmunoVaccine Technologies Enters Into An Agreement With Defence Research and Development Canada 68
ImmunoVaccine Enters Into Collaboration Agreement With National Institutes of Health 69
Bioject Medical Technologies Enters Into Research Collaboration With ImmunoVaccine Technologies 70
ImmunoVaccine Technologies Enters Into Co-Development Agreement With DRDC 71
Licensing Agreements 72
Immunovaccine Enters Into License Agreement With Merck 72
Immunotope Enters Into Licensing Agreement With ImmunoVaccine Technologies 74
Pharmexa Enters Into Licensing Agreement With ImmunoVaccine Technologies 75
Equity Offering 76
Immunovaccine Completes Private Placement Of Common Stock For $2.8 Million 76
Immunovaccine Completes Public Offering Of $7.22 Million 78
Acquisition 80
ImmunoVaccine Completes Reverse Acquisition Of Rhino Resources 80
ImmunoVaccine Acquires Immunotope 81

Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 84
Disclaimer 84

List of Tables


Immunovaccine, Inc., Key Information 7
Immunovaccine, Inc., Key Facts 7
Immunovaccine, Inc. Pipeline by Indication, 2012 9
Immunovaccine, Inc. Pipeline by Stage of Development, 2012 11
Immunovaccine, Inc. Monotherapy Products in Pipeline, 2012 12
Immunovaccine, Inc. Combination Treatment Modalities in Pipeline, 2012 13
Immunovaccine, Inc. Phase I, 2012 14
Immunovaccine, Inc. Pre-Clinical, 2012 15
Immunovaccine, Inc. Discovery, 2012 16
Immunovaccine, Inc. Pipeline By Therapeutic Class, 2012 32
Immunovaccine, Inc. Pipeline By Route of Administration, 2012 33
Immunovaccine, Inc. Pipeline Products By Mechanism of Action, 2012 34
Immunovaccine, Inc. Recent Pipeline Updates, 2012 35
Immunovaccine, Inc. - Discontinued Pipeline Products, 2012 38
Immunovaccine, Inc., Subsidiaries 39
Immunovaccine, Inc., Deals Summary 49
Immunovaccine Enters Into Co-Development Agreement With Weill Cornell Medical College For Anti-Cocaine Vaccine 51
ImmunoVaccine Technologies Enters Into Research Agreement With CIMAB 52
Immunovaccine Technologies Enters Into Research Agreement With OncoTherapy Science 53
ImmunoVaccine Enters Into Agreement With IRX Therapeutics 54
Immunovaccine Enters Into Co-Development Agreement With Oncothyreon 55
Immunovaccine Enters Into Research Agreement With Vaxil BioTherapeutics 56
ImmunoVaccine Enters Into Research Agreement With Dana-Farber 57
ImmunoVaccine Enters Into Research Agreement With National Cancer Institute 62
Immunovaccine Expands Research Agreement With Defence Research And Development Canada 63
ImmunoVaccine Technologies Enters Into Agreement With Scancell 64
ImmunoVaccine Enters Into Research Agreement With Yokohama City University 65
ImmunoVaccine Technologies Enters Into Research Agreement With FIT Biotech 66
ImmunoVaccine Technologies Enters Into Agreement With NRC Institute for Biodiagnostics 67
ImmunoVaccine Technologies Enters Into An Agreement With Defence Research and Development Canada 68
ImmunoVaccine Enters Into Collaboration Agreement With National Institutes of Health 69
Bioject Medical Technologies Enters Into Research Collaboration With ImmunoVaccine Technologies 70
ImmunoVaccine Technologies Enters Into Co-Development Agreement With DRDC 71
Immunovaccine Enters Into License Agreement With Merck 72
Immunotope Enters Into Licensing Agreement With ImmunoVaccine Technologies 74
Pharmexa Enters Into Licensing Agreement With ImmunoVaccine Technologies 75
Immunovaccine Completes Private Placement Of Common Stock For $2.8 Million 76
Immunovaccine Completes Public Offering Of $7.22 Million 78
ImmunoVaccine Completes Reverse Acquisition Of Rhino Resources 80
ImmunoVaccine Acquires Immunotope 81

List of Figures


Immunovaccine, Inc. Pipeline by Indication, 2012 9
Immunovaccine, Inc. Pipeline by Stage of Development, 2012 11
Immunovaccine, Inc. Monotherapy Products in Pipeline, 2012 12
Immunovaccine, Inc. Combination Treatment Modalities in Pipeline, 2012 13
Immunovaccine, Inc. Pipeline By Therapeutic Class, 2012 32
Immunovaccine, Inc. Pipeline By Route of Administration, 2012 33
Immunovaccine, Inc. - Pipeline Products By Mechanism of Action, 2012 34

Upcoming Reports:

Multiple Myeloma Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2014 - 2020
By - Transparency Market Research
Multiple myeloma is a blood disorder related to leukemia and lymphoma, since it generally arises in bone marrow. In multiple myeloma, certain white blood cells (WBCs) begin to proliferate abnormally within the bone marrow. These cells are known as plasma cells. Plasma cells are responsible for manufacturing antibodies in the body that help fight against any infection. In multiple myeloma, excessive plasma cells release abnormal level of proteins in blood and bones. These excess levels of proteins accumulate throughout the body, and result in damaging organs. The plasma cells while...
Laundry Care Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
Laundry care market is changing drastically since past few years as consumers have started finding value in their purchases. With US economy still recovering from economic downturn, many consumers are evaluating their purchasing habits to ensure that they obtain greatest value for their money. Increasing preference for scented laundry care products and allergenic/ green products, and development of new products is gaining consumer acceptance and accelerating the growth of laundry care industry. Most market segments are growing at more than 5% growth rate annually. Detergent liquid...
Smart Antenna Market - Global Industry Analysis, Market Size, Share, Growth, And Forecast, 2012 - 2018
By - Transparency Market Research
Smart antennas are also known as multiple antennas or adaptive antennas (MIMO) and are used for identifying the direction of the arriving signal at the receiver or transmitter or both. Owing to authorization of 802.11 standards along with increasing applications of wireless technology in mobile communication and defense, the global market for smart antennas is expected to grow at a significant rate from 2012 to 2018.  Smart antennas are set to bring a revolution in wireless communication systems with their potential to implement more powerful, efficient, and cost...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Private Schools Have Higher Male Teaching Staff Than State Schools: Report
Oct 22, 2014  
Private and state education has always been a matter of debate across the UK. A recent study has shown that when it comes to teaching employment options, the difference between state-run and private education in terms of gender balance is absolutely clear.  A report by the Independent Schools Council (ISC) shows that while women dominate both the education medium, the number of...
Abbots First Australian Renewable Energy Deal Rejected
Oct 22, 2014  
The Abbot government’s initial deal for a renewable energy plan has been immediately rejected by the clean energy industry and Labor. The negotiations are about a bipartisan agreement regarding the future of the Australian renewable energy target. The Labor party rejected the first plan as being a job-killer before it was even announced. The plan, they said, would protect solar...
Chemical Production in Europe Flatlines in First Seven Months of 2014
Oct 21, 2014  
The recently published report by European Chemical Industry Council (Cefic) shows overall chemical production in Europe has flatlined in first seven months of this year. Though the initial four months showed a positive trend, the production volumes dropped in July 2014 and in the following months as well. The contraction in output in the three consecutive months has nullified the upward trend...
Actavis to Compete for Omega Pharma
Oct 20, 2014  
Actavic Plc has declared that it will become one of the bidders for the Omega Pharma NV deal, as the United States based drug maker keeps searching for more takeovers. Actavis will be competing against Boehringer Ingelheim GmbH, Sanofi and Perrigi Co. for Omega Pharma. Actavis places themselves as a potential suitor along with quarry in a multitude of potential pharma combinations....
Sale of iPhone Fuels UKs s
Oct 20, 2014  
With the sale of Apple Inc.’s latest smartphone, consumer expenditure on electronics has registered a three-year high this September. The new iPhone 6 and iPhone 6 Plus were launched in the U.K. on September 19 and buyers from across the country raced to purchase the newest smartphone. Both these smartphones are so far the fastest selling Apple products with a sale of over 10 million...